Centre Hospitalier Universitaire de Poitiers-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2022

  1. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

2020

  1. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

    Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 283-306

2018

  1. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials

    Hematological Oncology, Vol. 36, Núm. 2, pp. 463-470